Zevra Therapeutics (ZVRA) Amortization of Deferred Charges (2014 - 2026)

Zevra Therapeutics (ZVRA) posted Amortization of Deferred Charges of $118000.0 for Q1 2026, down 21.33% on a QoQ basis from $150000.0 in Q1 2021.

Zevra Therapeutics (ZVRA) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends

Zevra Therapeutics' Amortization of Deferred Charges history runs 9 years deep, the most recent figure standing at $118000.0 for Q1 2026.

Quarterly Amortization of Deferred Charges changed N/A year-over-year to $118000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118000.0 (changed N/A YoY) and the FY2025 annual result came in at $602000.0, up 9.06% from the prior year.
Amortization of Deferred Charges was $118000.0 for Q1 2026 at Zevra Therapeutics, down from $150000.0 in the prior quarter.
Across five years, Amortization of Deferred Charges topped out at $118000.0 in Q1 2026 and bottomed at $118000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Zevra Therapeutics	570.04 Mn	369.43 Mn	34.32 Mn

Download Data